Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Stocks in this Quantisnow insightHealth Care
Historical context for SLRX
Across the 6 sessions after earlier SLRX headlines, the stock closed higher 3 times and lower 3 times, with a median move of 6.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SLRX | SPY |
|---|---|---|---|
| Dec 19, 2025 | Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting | +2.1% | +0.6% |
| Dec 18, 2025 | Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform | +2.8% | +0.8% |
| Dec 1, 2025 | Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study | -7.4% | -0.5% |
| Nov 19, 2025 | Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" | -8.3% | +0.4% |
| Nov 13, 2025 | Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger | +5.2% | -1.7% |
| Nov 11, 2025 | Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering | -51.0% | +0.2% |
Quantisnow market dataNASDAQ
SLRX
Salarius Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for SLRX
Full SLRX profile on Quantisnow Follow SLRX and get a push notification the moment its next story breaks.